NewcelX(NASDAQ) NCEL

Market Cap$15.56M

Since IPO (2025)-60%

5 Year-100%

1 Year-87%

1 Month-17%

$2.95

+1.96%

+0.06Today

NewcelX last closing stock price
Metric	Price	Date
Last close	USD 2.89	2026-09-24

NewcelX stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-14.5%	USD 3.38	2026-09-17
1 month	-16.95%	USD 3.48	2026-08-25
3 month	-20.6%	USD 3.64	2026-06-26
Year to date	+52.11%	USD 1.90	2025-12-31
1 year	-86.5%	USD 21.40	2025-09-24
3 year	-99.06%	USD 306.00	2023-09-25
5 year	-99.72%	USD 1,036.00	2021-09-24
Since inception	-60.36%	USD 7.29	2025-10-31

NewcelX Financials at a Glance

Market Cap

$15.56M

Revenue (TTM)

$0.00

Net Income (TTM)

-$720.10K

EPS (TTM)

-$17.34

P/E Ratio

-0.17

Dividend

$0.00

Beta (Volatility)

0.41 (Low)

Dividend

$0.00

Beta (Volatility)

0.41 (Low)

Price

$2.95

Volume

4,772

Open

$2.99

Price

$2.95

Volume

4,772

Open

$2.99

Previous Close

$2.95

Daily Range

$2.95 - $3.21

52-Week Range

$1.83 - $24.60

Estimated Earnings Date

Mar 3, 2027

Dividend

$0.00

Beta (Volatility)

0.41 (Low)

Price

$2.95

Volume

4,772

Open

$2.99

Previous Close

$2.95

Daily Range

$2.95 - $3.21

52-Week Range

$1.83 - $24.60

Estimated Earnings Date

Mar 3, 2027

NCEL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NewcelX

NewcelX Ltd. is a biotechnology firm based in Zurich, Switzerland, established in 2008. The company is focused on developing innovative therapeutic solutions for neurodegenerative and metabolic diseases through cell-based and small-molecule approaches.

Products and Services

Innovative treatments for neurodegenerative diseases
Development of small-molecule therapies
Research in metabolic disease solutions

Growth Outlook

Market demand for neurodegenerative treatments is increasing
Expansion into new therapeutic areas is planned
Strong pipeline of innovative therapies under development

Financial Highlights

Recent quarterly net income of $4.35 million
Cash and cash equivalents of $2.2 million as of Q4 2025
Significant reduction in operating expenses over the last year

NewcelX Ltd. is positioned in a growing market with a focus on addressing significant healthcare challenges. The company's innovative approach to treatment development, combined with a strong financial position, presents a compelling opportunity for potential investors. The recent quarterly performance indicates a positive trajectory, with a notable net income and a solid cash position. As the demand for effective therapies in neurodegenerative and metabolic diseases continues to rise, NewcelX Ltd. is well-placed to capitalize on these trends.

AI Generated • Sep 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Ronen Twito

Website

newcelx.net

Headquarters

Kloten, ZH 8302, CH

NCEL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

21.75%

Return on Capital

-32.53%

Return on Assets

14.90%

Earnings Yield

-5.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.56M

Shares Outstanding

5.38M

Volume

4.77K

Avg. Volume

17.92K

Financials (TTM)

Gross Profit

-$22.60K

Operating Income

-$11.04M

EBITDA

-$7.61M

Operating Cash Flow

-$7.69M

Capital Expenditure

-$3.93K

Free Cash Flow

-$7.69M

Cash & ST Invst.

$710.00K

Total Debt

$392.00K

NewcelX Performance Analysis

NewcelX annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

NewcelX sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	N/A
Q2	2025-06-30	N/A
Q4	2025-12-31	N/A
Q2	2026-06-30	N/A

NewcelX annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -335.23	3.5%
2023	2023-12-31	USD -127.54	-62.0%
2024	2024-12-31	USD -24.32	-80.9%
2025	2025-12-31	USD -2.16	-91.1%

NewcelX sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	-409.9%
Q2	2025-06-30	-6.1%
Q4	2025-12-31	112.3%
Q2	2026-06-30	-174.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$23.00K

-303.2%

Gross Margin

0.00%

N/A

Market Cap

$15.56M

N/A

Market Cap/Employee

$1.41M

N/A

Employees

N/A

Net Income

-$2.90M

-42.4%

EBITDA

-$2.81M

-44.5%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$710.00K

+28.4%

Total Debt

$392.00K

-77.1%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$392.00K

-77.1%

Return on Assets

14.90%

N/A

Return on Invested Capital

-1.15%

N/A

Free Cash Flow

-$2.87M

-87.7%

Operating Cash Flow

-$2.87M

-87.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KTTAPasithea Therapeutics Corp.

KTTAPasithea Therapeutics Corp.$0.50-2.82%

CEROCERo Therapeutics Holdings, Inc.

CEROCERo Therapeutics Holdings, Inc.$0.01-7.56%

OCEAOcean Biomedical, Inc.

OCEAOcean Biomedical, Inc.$0.00+0.00%

NUWENuwellis, Inc.

NUWENuwellis, Inc.$0.78-3.87%

BACKIMAC Holdings, Inc.

BACKIMAC Holdings, Inc.$0.00+0.00%

BCTXWBriaCell Therapeutics Corp.

BCTXWBriaCell Therapeutics Corp.$0.00-0.00%

CELUCelularity Inc.

CELUCelularity Inc.$1.38+4.55%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

GLNDGreenland Energy

GLNDGreenland Energy$5.54+3.55%

INTCIntel

INTCIntel$123.00-3.45%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.94-3.02%

NVDANvidia

NVDANvidia$225.07+0.22%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.87+3.90%

ONDSOndas

ONDSOndas$7.64+0.53%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$32.43-3.57%

Questions About NCEL

What is the current price of NewcelX?

NewcelX is trading at $2.95 per share.

What is the 52-week range for NewcelX?

Over the past 52 weeks, NewcelX has traded between $1.83 and $24.60.

How much debt does NewcelX have?

As of the most recent reporting period, NewcelX reported total debt of $355.00K.

How much cash does NewcelX have on hand?

NewcelX reported $2.20M in cash and cash equivalents in its most recent financial results.

What is NewcelX’s dividend yield?

NewcelX does not currently have a dividend yield.

NewcelX(NASDAQ) NCEL

NewcelX Financials at a Glance

NCEL News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About NewcelX

NCEL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

NewcelX Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NCEL

What is the current price of NewcelX?

What is the 52-week range for NewcelX?

How much debt does NewcelX have?

How much cash does NewcelX have on hand?

What is NewcelX’s dividend yield?

Premium Investing Services